Early Compliance and Efficacy of Sublingual Immunotherapy in Patients with Allergic Rhinitis for House Dust Mites
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Objectives. Sublingual immunotherapy (SLIT) has recently received much attention around the world as a treatment for allergic rhinitis. This study aimed to investigate the efficacy and adverse effects of SLIT in Korean patients with allergic rhinitis caused by house dust mites. The treatment compliance and the patient satisfaction with SLIT were also assessed. Methods. The patients who were sensitized to Dermatophagoides pteronyssinus and Dermatophagoides farinae and who started SLIT between November 2007 and July 2008 were included in this study. The symptom questionnaires, which included items on rhinorrhea, sneezing, nasal obstruction, itchy nose, olfactory disturbance, eye discomfort and sleep disturbance, were obtained before and 6 months after SLIT. The patient satisfaction and the adverse effects were also investigated. Results. One hundred forty-two patients started SLIT and 98 of them continued SLIT for 6 months or more. Ninety-two of the 98 patients completed the questionnaires. The duration of receiving SLIT was 9.8 months on average (range, 6 to 13 months). All the symptoms of allergic rhinitis were improved with SLIT. Forty-five percent of the patients were satisfied for SLIT, while 12% were unsatisfied. The incidence of adverse effects was 12% during maintenance therapy, although it was 48% during the up-dosing phase. The drop-out rate of SLIT was 31.0%. Conclusion. The subjective symptoms were improved with SLIT in Korean patients with allergic rhinitis for house dust mites. Yet the drop out rate was high despite of the symptomatic improvement.
Abstract
Objectives. Sublingual immunotherapy (SLIT) has recently received much attention around the world as a treatment for allergic rhinitis. This study aimed to investigate the efficacy and adverse effects of SLIT in Korean patients with allergic rhinitis caused by house dust mites. The treatment compliance and the patient satisfaction with SLIT were also assessed. Methods. The patients who were sensitized to Dermatophagoides pteronyssinus and Dermatophagoides farinae and who started SLIT between November 2007 and July 2008 were included in this study. The symptom questionnaires, which included items on rhinorrhea, sneezing, nasal obstruction, itchy nose, olfactory disturbance, eye discomfort and sleep disturbance, were obtained before and 6 months after SLIT. The patient satisfaction and the adverse effects were also investigated. Results. One hundred forty-two patients started SLIT and 98 of them continued SLIT for 6 months or more. Ninety-two of the 98 patients completed the questionnaires. The duration of receiving SLIT was 9.8 months on average (range, 6 to 13 months). All the symptoms of allergic rhinitis were improved with SLIT. Forty-five percent of the patients were satisfied for SLIT, while 12% were unsatisfied. The incidence of adverse effects was 12% during maintenance therapy, although it was 48% during the up-dosing phase. The drop-out rate of SLIT was 31.0%. Conclusion. The subjective symptoms were improved with SLIT in Korean patients with allergic rhinitis for house dust mites. Yet the drop out rate was high despite of the symptomatic improvement.
참고문헌 (22)
- Esch RE, "Sublingual immunotherapy", Curr Opin Otolaryngol Head Neck Surg, 16(3), pp.260~264 (2008)
- Guez S, "House-dust-mite sublingualswallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study", Allergy, 55(4), pp.369~375 (2000)
- Bousquet J, "Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)", Allergy, 63(86), pp.8~160 (2008)
- Wilson DR, "Sublingual immunotherapy for allergic rhinitis", Cochrane Database Syst Rev, (2), pp.CD002893~ (2003)
- Casanovas M, "Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually", J Investig Allergol Clin Immunol, 4(6), pp.305~314 (1994)
- Durham SR, "Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma", J Allergy Clin Immunol, 97(6), pp.1356~1365 (1996)
- Pradalier A, "Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis", Allergy, 54(8), pp.819~828 (1999)
- Purello-D’Ambrosio F, "Sublingual immunotherapy: a double-blind, placebocontrolled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both", Allergy, 54(9), pp.968~973 (1999)
- Dahl R, "Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis", J Allergy Clin Immunol, 118(2), pp.434~440 (2006)
- Durham SR, "Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis", J Allergy Clin Immunol, 117(4), pp.802~809 (2006)
- Nuhoglu Y, "Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period", J Investig Allergol Clin Immunol, 17(6), pp.375~378 (2007)
- Passalacqua G, "Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy", Inflamm Allergy Drug Targets, 5(1), pp.43~51 (2006)
- 김동영, "알레르기비염 환자에서 면역치료에 대한 만족도 분석", 대한이비인후과학회지 두경부외과학, 47(2), pp.132~138 (2004), 대한이비인후과학회
- Frew AJ, "Sublingual immunotherapy", N Engl J Med, 358(21), pp.2259~2264 (2008)
- Antico A, "Anaphylaxis by latex sublingual immunotherapy", Allergy, 61(10), pp.1236~1237 (2006)
- Dunsky EH, "Anaphylaxis to sublingual immunotherapy", Allergy, 61(10), pp.1235~ (2006)
- Eifan AO, "Anaphylaxis to multiple pollen allergen sublingual immunotherapy", Allergy, 62(5), pp.567~568 (2007)
- Canonica GW, "Sublingual immunotherapy in the treatment of adult allergic rhinitis patients", Allergy, 61(81), pp.20~23 (2006)
- Lombardi C, "Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study", Allergy, 56(10), pp.989~992 (2001)
- Rienzo VD, "Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years", Clin Exp Allergy, 35(5), pp.560~564 (2005)
- Roder E, "Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial", Clin Exp Allergy, 38(10), pp.1659~1667 (2008)
- Passalacqua G, "Quantitative assessment of the compliance with a oncedaily sublingual immunotherapy regimen in real life (EASY Project:Evaluation of A novel SLIT formulation during a Year)", J Allergy Clin Immunol, 117(4), pp.946~948 (2006)